Food oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?

Basit Öğe Kaydı
dc.authorscopusid56331939200
dc.authorscopusid57192870303
dc.authorscopusid9036191300
dc.authorscopusid7004473191
dc.contributor.authorAkarcan, S.E.
dc.contributor.authorŞenol, H.D.
dc.contributor.authorGülen, F.
dc.contributor.authorDemir, E.
dc.date.accessioned2024-08-25T18:46:26Z
dc.date.available2024-08-25T18:46:26Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractOral immunotherapy (OIT) has gained popularity recently for IgE-mediated food allergy. Omalizumab (OMZ) has been used in patients (10-20%) who have too severe/frequent allergic reactions (AR) to continue OIT, to reduce these reactions. In this study, it was aimed to compare two groups of patients who completed OIT with and without OMZ and to seek determinants predicting the need of this treatment. It was also aimed to share the clinical findings regarding the long-term use of OMZ and the withdrawal process. Forty-one patients were started OIT and 93% could be desensitized. Two groups were similar in means of demographic characteristics, and clinical and laboratory findings. The patients who needed OMZ during OIT had also lower reaction doses during oral challenge (p = 0.037). Higher AR rate in this group declined after starting OMZ (p < 0.001). The injection intervals of OMZ were gradually extended. Most patients were able to discontinue OMZ (81%). There were no severe reactions during drug withdrawal attempts. The low reaction thresholds during oral food challenge may give a clue about OMZ requirement during OIT. It may be an option to start the treatment before OIT if reaction was seen in the first few steps of the oral food challenge. For the sake of safety, extension of injection intervals should be preferred instead of abruptly stopping OMZ.en_US
dc.identifier.doi10.15586/aei.v51i6.907
dc.identifier.endpage111en_US
dc.identifier.issn1578-1267
dc.identifier.issue6en_US
dc.identifier.pmid37968804en_US
dc.identifier.scopus2-s2.0-85177092303en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage104en_US
dc.identifier.urihttps://doi.org/10.15586/aei.v51i6.907
dc.identifier.urihttps://hdl.handle.net/11454/101900
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofAllergologia et immunopathologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectallergic reactionsen_US
dc.subjectfood allergyen_US
dc.subjectfood challenge testen_US
dc.subjectomalizumaben_US
dc.subjectoral immunotherapyen_US
dc.subjectallergenen_US
dc.subjectanti-IgE antibodiesen_US
dc.subjectimmunosuppressive agenten_US
dc.subjectomalizumaben_US
dc.subjectdesensitizationen_US
dc.subjectfood allergyen_US
dc.subjecthumanen_US
dc.subjectoral drug administrationen_US
dc.subjectAdministration, Oralen_US
dc.subjectAllergensen_US
dc.subjectDesensitization, Immunologicen_US
dc.subjectFood Hypersensitivityen_US
dc.subjectHumansen_US
dc.subjectImmunosuppressive Agentsen_US
dc.subjectOmalizumaben_US
dc.titleFood oral immunotherapy: Any distinguishing factors predicting the need of anti-IgE?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu